Methyl 4'-amino-2'-methyl[1,1'-biphenyl]-4-carboxylate | 188593-21-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Methyl 4'-amino-2'-methyl[1,1'-biphenyl]-4-carboxylate
• 英文别名: methyl 4-(4-amino-2-methylphenyl)benzoate
• CAS: 188593-21-7
• 化学式: C₁₅H₁₅NO₂
• 分子量: 241.28
• InChiKey: HQYVJAIESXYXDK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Methyl 4'-amino-2'-methyl[1,1'-biphenyl]-4-carboxylate 、 氯乙基异氰酸酯 以 二氯甲烷 、 甲苯 为溶剂， 反应 72.0h， 以This gave the title compound (0.99 g, 69%) as a cream solid的产率得到N-(2-Chloroethyl)-N'-(4'-methoxycarbonyl-2-methylbiphenyl-4-yl)urea
  参考文献：
  名称：

  Tetracyclic spiro compounds as 5HT.sub.1B receptor antagonists

  摘要：

  化合物的化学式(I)，其中B为氧或硫，D为氮，R.sup.6和R.sup.7形成一个环，m为2，R为公式(i)的取代的拉丹环：##STR1## 其中p为1，P为含有一个或两个杂原子的取代或未取代的双环环或P为未取代或取代的含有一个或两个杂原子的5-至7-成员饱和环；X、Y、Z、E、G、R.sup.3、R.sup.4、R.sup.5、R.sup.8、R.sup.9和R.sup.10如规范所定义。

  公开号：

  US06100272A1
• 作为产物：
  描述：

  氯化亚砜 、 4'-Amino-2'-methylbiphenyl-4-carboxylic acid 、 甲醇 在 hydrochloride salt 作用下， 反应 3.0h， 以to yield the title compound (9.16 g, 89%) as the hydrochloride salt的产率得到Methyl 4'-amino-2'-methyl[1,1'-biphenyl]-4-carboxylate
  参考文献：
  名称：

  Tetracyclic spiro compounds as 5HT.sub.1B receptor antagonists

  摘要：

  化合物的化学式(I)，其中B为氧或硫，D为氮，R.sup.6和R.sup.7形成一个环，m为2，R为公式(i)的取代的拉丹环：##STR1## 其中p为1，P为含有一个或两个杂原子的取代或未取代的双环环或P为未取代或取代的含有一个或两个杂原子的5-至7-成员饱和环；X、Y、Z、E、G、R.sup.3、R.sup.4、R.sup.5、R.sup.8、R.sup.9和R.sup.10如规范所定义。

  公开号：

  US06100272A1

文献信息

• Piperazine derivatives their preparation and uses in therapy
  申请人：——

  公开号：US20040142925A1

  公开（公告）日：2004-07-22

  Compounds of formula (I) or a pharmaceutically acceptable salt thereof are disclosed: 1 in which R a is a group of formula (i) 2 wherein P 2 is phenyl, naphthyl, heteroaryl or a 5 to 7 membered heterocyclic ring; P 3 is phenyl, naphthyl or heteroaryl; R 1 is NR 4 COR 5 , NR 4 SO 2 R 5 , CH 2 NR 4 SO 2 R 5 , CH 2 NR 4 COR 5 or CH 2 NR 4 CO 2 R 5 where R 4 and R 5 are independently hydrogen or C 1-6 alkyl; R 2 and R 3 are independently halogen, C 1-6 alkyl, C 3-6 cycloalkyl, C 1-6 alkoxy, COC 1-6 alkyl, haloC 1-6 alkyl, cyano or NR 6 R 7 where R 6 and R 7 are independently hydrogen or C 1-6 alkyl; b and c are independently 0, 1, 2 or 3; Y is a single bond, CH 2 or NH; W is —(CR 9 R 10 ) t - where t is 2, 3 or 4 and R 9 and R 10 are independently hydrogen or C 1-6 alkyl or W is a group CH═CH; R b is hydrogen, halogen, C 1-6 alkyl, haloC 1-6 alkyl, COC 1-6 alkyl, cyano or C 1-6 alkoxy; and R c is hydrogen or C 1-6 alkyl. Processes for preparation of the compounds and their uses in therapy, particularly depression, are also disclosed.

  揭示了式（I）的化合物或其药学上可接受的盐：其中，R是式（i）的基团，式中P2是苯基、萘基、杂环芳基或5至7成员杂环环；P3是苯基、萘基或杂环芳基；R1是NR4COR5、NR4SO2R5、CH2NR4SO2R5、CH2NR4COR5或CH2NR4CO2R5，其中R4和R5独立地为氢或C1-6烷基；R2和R3独立地为卤素、C1-6烷基、C3-6环烷基、C1-6烷氧基、COC1-6烷基、卤基C1-6烷基、氰基或NR6R7，其中R6和R7独立地为氢或C1-6烷基；b和c独立地为0、1、2或3；Y为单键、CH2或NH；W为—（CR9R10）t-，其中t为2、3或4，且R9和R10独立地为氢或C1-6烷基，或W为基团CH═CH；Rb为氢、卤素、C1-6烷基、卤基C1-6烷基、COC1-6烷基、氰基或C1-6烷氧基；Rc为氢或C1-6烷基。还揭示了制备这些化合物的方法以及它们在治疗中的用途，特别是抑郁症。
• Biphenyl(thio)amide and bipennylethan(thi) one derivatives, their
  申请人：SmithKline Beecham p.l.c.

  公开号：US05972935A1

  公开（公告）日：1999-10-26

  The invention relates to novel heterocyclic compounds of formula (I) or a salt or N-oxide thereof, in which R is a group of formulae (i), (ii) or (iii), where R.sup.1 is hydrogen, halogen, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, COC.sub.1-6 akyl, C.sub.1-6 alkoxy, hydroxy, hydroxyC.sub.1-6 alkyl, hydroxyC.sub.1-6 alkoxy, C.sub.1-6 alkoxyC.sub.1-6 alkoxy, acyle, nitro, trifluoromethyl, cyano, SR.sup.9, SOR.sup.9, SO.sub.2 R.sup.9, NR.sup.9 CONR.sup.10 R.sup.11, NR.sup.10 SO.sub.2 R.sup.11, SO.sub.2 NR.sup.11 r.sup.11, SO.sub.2 NR.sup.10 R.sup.11, CO.sub.2 R.sup.10, CONR.sup.10 R.sup.11, CO.sub.2 NR.sup.10 R.sup.11, CONR.sup.10 (CH.sub.2).sub.a CO.sub.2 R.sup.11, (CH.sub.2).sub.a NR.sup.10 R.sup.11, ##STR1## (CH.sub.2).sub.a CONR.sup.10 R.sup.11, (CH.sub.2).sub.a COR.sup.11, (CH.sub.2).sub.a CO.sub.2 C.sub.1-6 alkyl, CO.sub.2 (CH.sub.2).sub.a OR.sup.10, NR.sup.10 R.sup.11, N.dbd.CNR.sup.9 NR.sup.10 R.sup.11, NR.sup.10 CO(CH.sub.2).sub.a NR.sup.10 R.sup.11, NR.sup.10 CO.sub.2 R.sup.11, CONHNR.sup.10 R.sup.11, CR.sup.10 .dbd.NOR.sup.11, CNR.sup.10 .dbd.NOR.sup.11, where R.sup.9, R.sup.10 and R.sup.11 are independently hydrogen or C.sub.1-6 alkyl and a is 1 to 4; or R.sup.1 is a group --X--R.sup.12 where R.sup.12 is an optionally substituted 5- to 7-membered heterocyclic ring containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulphur and X is a bond, O, S, CH.sub.2, C.dbd.O, NR.sup.13 CO or NR.sup.13 where R.sup.13 is hydrogen or C.sub.1-6 alkyl; R.sup.4 and R.sup.5 are independently hydrogen, halogen, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, C.sub.3-6 cycloalkenyl, C.sub.1-6 alkoxy, hydroxyC.sub.1-6 alkyl, C.sub.1-6 alkylOC.sub.1-6 alkyl, acyl, aryl, acyloxy, hydroxy, nitro, trifluoromethyl, cyano, CO.sub.2 R.sup.10, CONR.sup.10 R.sup.11, NR.sup.10 R.sup.11 where R.sup.10 and R.sup.11 are independently hydrogen or C.sub.1-6 alkyl, or R.sup.4 and R.sup.5 together form a group --CH.sub.2).sub.r --R.sup.14 --(CH.sub.2).sub.s -- where R.sup.14 is O, S, CH.sub.2 or NR.sup.15 where R.sup.15 is hydrogen or C.sub.1-6 alkyl and r and s are independently 0, 1 or 2; R.sup.2 is hydrogen, C.sub.1-6 alkyl, optionally substituted aryl or optionally substituted heteroaryl; R.sup.3 is hydrogen or C.sub.1-6 alkyl or together with R.sup.8 forms a group (CH.sub.2).sub.q where q is 2, 3 or 4; Z is oxygen or sulphur, p is 1 or 2; P is an optionally substituted bicyclic ring optionally containing one to four heteroatoms; or P is an optionally substituted 5- to 7-membered saturated or partially saturated ring optionally containing one to three heteroatoms; and B is oxygen or sulphur, D is nitrogen, carbon or a CH group; R.sup.6 is hydrogen or C.sub.1-6 alkyl and R.sup.7 is C.sub.1-6 alkyl, C.sub.1-6 alkoxy or halogen, or R.sup.6 together with R.sup.7 forms a group --A-- where A is (CR.sup.16 R.sup.17).sub.t where t is 1, 2 or 3 and R.sup.16 and R.sup.17 are independently hydrogen or C.sub.1-6 alkyl or A is (CR.sup.16 R.sup.17).sub.u --J where u is 0, 1, or 2 and J is oxygen, sulphur, CR.sup.16 .dbd.C.sup.17, CR.sup.16 .dbd.N, CR.sup.16 NR.sup.17 or N.dbd.N; R.sup.18 and R.sup.19 are independently hydrogen or C.sub.1-6 alkyl; R.sup.20 and R.sup.21 are independently hydrogen, C.sub.1-6 alkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring containing one or two heteroatoms selected from oxygen, nitrogen or sulphur, m is 0 to 4; and Q is an optionally substituted 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur, processes for their preparation, and their use as 5-HT.sub.1D receptor antagonists.

  本发明涉及式（I）的新型杂环化合物或其盐或N-氧化物，其中R是式（i），（ii）或（iii）的基团，其中R.sup.1是氢，卤素，C.sub.1-6烷基，C.sub.3-6环烷基，COC.sub.1-6烷基，C.sub.1-6烷氧基，羟基，羟基C.sub.1-6烷基，羟基C.sub.1-6烷氧基，C.sub.1-6烷氧基C.sub.1-6烷氧基，酰基，硝基，三氟甲基，氰基，SR.sup.9，SOR.sup.9，SO.sub.2R.sup.9，NR.sup.9CONR.sup.10R.sup.11，NR.sup.10SO.sub.2R.sup.11，SO.sub.2NR.sup.11r.sup.11，SO.sub.2NR.sup.10R.sup.11，CO.sub.2R.sup.10，CONR.sup.10R.sup.11，CO.sub.2NR.sup.10R.sup.11，CONR.sup.10（CH.sub.2）.sub.aCO.sub.2R.sup.11，（CH.sub.2）.sub.aNR.sup.10R.sup.11，##STR1##（CH.sub.2）.sub.aCONR.sup.10R.sup.11，（CH.sub.2）.sub.aCOR.sup.11，（CH.sub.2）.sub.aCO.sub.2C.sub.1-6烷基，CO.sub.2（CH.sub.2）.sub.aOR.sup.10，NR.sup.10R.sup.11，N.dbd.CNR.sup.9NR.sup.10R.sup.11，NR.sup.10CO（CH.sub.2）.sub.aNR.sup.10R.sup.11，NR.sup.10CO.sub.2R.sup.11，CONHNR.sup.10R.sup.11，CR.sup.10.dbd.NOR.sup.11，CNR.sup.10.dbd.NOR.sup.11，其中R.sup.9，R.sup.10和R.sup.11独立地为氢或C.sub.1-6烷基，a为1至4；或R.sup.1为--X--R.sup.12的基团，其中R.sup.12是含有1至4个氧，氮或硫杂原子的可选择取代的5-至7元杂环环，X为键，O，S，CH.sub.2，C.dbd.O，NR.sup.13CO或NR.sup.13，其中R.sup.13为氢或C.sub.1-6烷基；R.sup.4和R.sup.5独立地为氢，卤素，C.sub.1-6烷基，C.sub.3-6环烷基，C.sub.3-6环烯基，C.sub.1-6烷氧基，羟基C.sub.1-6烷基，C.sub.1-6烷氧基C.sub.1-6烷基，酰基，芳基，酰氧基，羟基，硝基，三氟甲基，氰基，CO.sub.2R.sup.10，CONR.sup.10R.sup.11，NR.sup.10R.sup.11，其中R.sup.10和R.sup.11独立地为氢或C.sub.1-6烷基，或R.sup.4和R.sup.5一起形成基团--CH.sub.2）.sub.r--R.sup.14--（CH.sub.2）.sub.s--，其中R.sup.14为O，S，CH.sub.2或NR.sup.15，其中R.sup.15为氢或C.sub.1-6烷基，r和s独立地为0，1或2；R.sup.2为氢，C.sub.1-6烷基，可选择取代的芳基或可选择取代的杂芳基；R.sup.3为氢或C.sub.1-6烷基，或与R.sup.8一起形成基团（CH.sub.2）.sub.q，其中q为2、3或4；Z为氧或硫，p为1或2；P是可选择取代的双环环，可选择包含一到四个杂原子；或P是可选择取代的5-至7元饱和或部分饱和环，可选择包含一到三个杂原子；B为氧或硫，D为氮，碳或CH基团；R.sup.6为氢或C.sub.1-6烷基，R.sup.7为C.sub.1-6烷基，C.sub.1-6烷氧基或卤素，或R.sup.6与R.sup.7一起形成基团--A--，其中A为（CR.sup.16R.sup.17）.sub.t，其中t为1、2或3，R.sup.16和R.sup.17独立地为氢或C.sub.1-6烷基，或A为（CR.sup.16R.sup.17）.sub.u--J，其中u为0、1或2，J为氧，硫，CR.sup.16.dbd.C.sup.17，CR.sup.16.dbd.N，CR.sup.16NR.sup.17或N.dbd.N；R.sup.18和R.sup.19独立地为氢或C.sub.1-6烷基；R.sup.20和R.sup.21独立地为氢，C.sub.1-6烷基，芳基烷基，或与它们所连接的氮原子一起形成可选择取代的5-至7元杂环环，其中选自氧，氮或硫的一个或两个杂原子，m为0至4；Q为可选择取代的5-至7元杂环环，其中选自氧，氮或硫的1至3个杂原子，以及它们的制备方法和作为5-HT.sub.1D受体拮抗剂的用途。
• [DE] SUBSTITUIERTE ARYLALKYLTHIOALKYLTHIOPYRIDINE ZUR BEKÄMPFUNG VON HELICOBACTER-BAKTERIEN<br/>[EN] SUBSTITUTED ARYLALKYLTHIOALKYLTHIOPYRIDINES FOR USE IN THE CONTROL OF HELICOBACTER BACTERIA<br/>[FR] ARYLALKYLTHIOALKYLTHIOPYRIDINES SUBSTITUEES UTILISEES POUR LUTTER CONTRE DES BACTERIES HELICOBACTER
  申请人：BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH

  公开号：WO1995034554A1

  公开（公告）日：1995-12-21

  (DE) Verbindungen der Formel (I), worin die Substituenten und Symbole die in der Beschreibung angegebenen Bedeutungen haben, eignen sich zur Bekämpfung von Helicobacter-Bakterien.(EN) Described are compounds of formula (I) in which the substituents and symbols are as defined in the specification. Such compounds are suitable for use in the control of Helicobacter bacteria.(FR) L'invention concerne des composés de la formule (I) dans laquelle les substituants et les symboles ont les notations mentionnées dans la description. Ces composés s'utilisent dans la lutte contre des bactéries Helicobacter.

  （德）具有公式（I）的化合物，其中的替代基团和符号具有描述中提到的意义，适用于对抗螺旋状生物杆菌。（英文）描述的是形如（I）式的化合物，在这些化合物中所用的取代基团和符号均如说明书上所定义。这样的化合物可用于对抗螺旋状生物杆菌的防治。 （法）这种化合物可用于对抗螺旋状生物杆菌。
• SUBSTITUIERTE ARYLALKYLTHIOALKYLTHIOPYRIDINE ZUR BEKÄMPFUNG VON HELICOBACTER-BAKTERIEN
  申请人：Byk Gulden Lomberg Chemische Fabrik GmbH

  公开号：EP0764161A1

  公开（公告）日：1997-03-26
• PIPERIDINE DERIVATIVES
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP0888358A1

  公开（公告）日：1999-01-07